Results
76,342 records
Include
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | Kalish MatthewDirector |  DKNGDraftKings Inc.Option exercise | M | — 383.5K sh | Aug 14, 2026 |
Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramEvery ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | Kalish MatthewDirector | DKNGDraftKings Inc. Option exercise | M | — 383.5K sh | Aug 14, 2026 |
| 9 | Venkatesh VandanaEVP and Chief Legal Officer |  VZVERIZON COMMUNICATIONS INCGrant or award | A | $1,277 93 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 9 | Amoo-Gottfried Kofi OwusuDirector |  HIMSHims & Hers Health, Inc.Grant or award | A | — 13.2K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Goodwin William Carroll MurphyChief Legal & Strategy Officer |  OKLOOklo Inc.Option exercise | M | — 20.7K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Manuel AnjaDirector | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Payne Christopher DDirector | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Nofi MichaelChief Financial Officer |  EWTXEdgewise Therapeutics, Inc.Grant or award | A | — 48.8K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Taylor Randy JSee Remarks |  USFDUS Foods Holding Corp.Option exercise | M | — 5,199 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 9 | Mottola FrankSVP, Chief Tech. Ops. Officer |  SUPNSUPERNUS PHARMACEUTICALS, INC.Tax withholding | F | $37K 797 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Baetz Cary DEVP and CFO |  INRINFINITY NATURAL RESOURCES, INC.Grant or award | A | — 31.8K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Bruno Marc ACOO, U.S. Food & Facilities |  ARMKAramarkOption exercise | M | — 57.1K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 8 |  Kurtz GeorgeDirector, PRESIDENT AND CEO |  CRWDCrowdStrike Holdings, Inc.Open-market sale · 10b5-1 plan | SELL | $18K 80 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 8 | Watts Ryan J.Director, President and CEO |  DNLIDenali Therapeutics Inc.Gift | G | — 32.2K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 8 | Kurtz GeorgeDirector, PRESIDENT AND CEO | CRWDCrowdStrike Holdings, Inc. Open-market sale · 10b5-1 plan | SELL | $26K 120 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 7 | Grawunder UlfDirector |  ADAGAdagene Inc.Grant or award · 10b5-1 plan | A | — 20.0K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 5 | Carroll Patrick HarrisonChief Medical Officer | HIMSHims & Hers Health, Inc. Grant or award | A | — 260 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Russell Alan JDirector, Chief Scientific Officer | EWTXEdgewise Therapeutics, Inc. Grant or award | A | — 65.0K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Akerib AvidanVP, Associative Computing |  GSITGSI TECHNOLOGY INCGrant or award | A | — 40.0K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 5 | Perez Garcia Andrea GDirector | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Fukushima RyanCEO, Data |  TEMTempus AI, Inc.Gift | G | — 62.2K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Autor Deborah M.Director, Chief Policy Officer | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Russell Alan JDirector, Chief Scientific Officer | EWTXEdgewise Therapeutics, Inc. Grant or award | A | — 32.5K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Haas JasonDirector |  LGNDLIGAND PHARMACEUTICALS INCOption exercise | M | — 6,138 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 4 | Clark KyleDirector, SEE REMARKS |  BETABETA Technologies, Inc.Open-market sale · 10b5-1 plan | SELL | $763K 30.0K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 4 | Clark KyleDirector, SEE REMARKS | BETABETA Technologies, Inc. Open-market sale · 10b5-1 plan | SELL | $352K 15.0K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 2 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $410K 7,171 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 2 | Chuang Patrick T.Senior VP, Memory Design | GSITGSI TECHNOLOGY INC Grant or award | A | — 40.0K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 1 | Hooker David StevensDirector |  NPBNORTHPOINTE BANCSHARES INCOpen-market sale · 10b5-1 plan | SELL | $5,943 339 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 1 | Shackley Brian CharlesSVP, Chief Accounting Officer |  AVAVAeroVironment IncOpen-market sale · 10b5-1 plan | SELL | $41K 205 sh | Aug 14, 2026 traded Aug 14, 2026 |
| 1 | Hooker David StevensDirector | NPBNORTHPOINTE BANCSHARES INC Open-market sale · 10b5-1 plan | SELL | $421 24 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 1 | McNamara PeterChief Scientific Officer |  TECXTectonic Therapeutic, Inc.Open-market sale · 10b5-1 plan | SELL | $1,505 43 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 7,171 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Rezvan MitraChief Accounting Officer |  SAILSailPoint, Inc.Open-market sale · 10b5-1 plan | SELL | $24K 1,214 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 16.2K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 3,348 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | McNamara PeterChief Scientific Officer | TECXTectonic Therapeutic, Inc. Option exercise · 10b5-1 plan | M | — 43 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary |  VGVenture Global, Inc.Option exercise · 10b5-1 plan | M | — 555.6K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 0 | Bernstein HaroldPresident, R&D & CMO |  MAZEMaze Therapeutics, Inc.Option exercise · 10b5-1 plan | M | — 16.1K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $145K 2,074 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 0 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 2,074 sh | Aug 14, 2026 traded Aug 12, 2026 |